-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Amicus Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Amicus Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was $21.7M.
- Amicus Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was $5.21M.
- Amicus Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$77.2M, a 63.6% increase from 2022.
- Amicus Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$212M, a 2.75% decline from 2021.
- Amicus Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$206M, a 16.4% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)